Moxifloxacin Accord (Moxifloxacin)

Moxifloxacin Accord is a fluoroquinolone antibiotic used to manage bacterial infections of the respiratory and skin systems.

• Community‑acquired pneumonia: eradicates the causative bacteria and improves clinical outcomes.
• Acute bacterial sinusitis: reduces sinus inflammation by eliminating pathogenic organisms.
• Acute bacterial exacerbation of chronic bronchitis: controls bacterial overgrowth and relieves symptoms.
• Skin and soft‑tissue infections: targets susceptible Gram‑positive and Gram‑negative bacteria to promote healing.

• Moxifloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair. By binding to these enzymes, the drug prevents the supercoiling and separation of bacterial DNA strands, leading to halted bacterial cell division and eventual bacterial cell death. This bactericidal action is effective against a broad spectrum of Gram‑positive and Gram‑negative organisms.

Moxifloxacin Accord may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Diarrhea: loose stools, often self‑limiting.
• Headache: transient cranial discomfort.
• Dizziness: occasional vertiginous sensation.
• Rash: mild skin erythema or pruritus.
• Elevated liver enzymes: transient laboratory changes.

Serious or Rare Side Effects

• Tendon rupture: especially Achilles tendon, may occur without warning.
• QT interval prolongation: can precipitate cardiac arrhythmias.
• Severe allergic reaction: anaphylaxis, angioedema, or Stevens‑Johnson syndrome.
• Clostridioides difficile infection: colitis due to gut flora disruption.
• Hepatotoxicity: significant liver injury in rare cases.
• Peripheral neuropathy: persistent numbness or tingling.

Before prescribing Moxifloxacin Accord, clinicians should consider several safety measures.

• Assess renal function: dose adjustment may be required in impaired clearance.
• Monitor cardiac status: avoid in patients with known QT prolongation or electrolyte disturbances.
• Evaluate hypersensitivity: discontinue if signs of allergic reaction appear.
• Use cautiously in the elderly: increased risk of tendon injury and CNS effects.
• Avoid concomitant use with other QT‑prolonging agents: risk of arrhythmia.
• Store at room temperature: keep in the original pack, protect from moisture.

Moxifloxacin Accord can interact with other medicines, necessitating careful review.

Major Interactions (Avoid)

• Antacids containing aluminum or magnesium: reduce absorption of the drug.
• Warfarin: may increase anticoagulant effect and bleeding risk.
• Systemic corticosteroids: heightened risk of tendon rupture.
• Other QT‑prolonging drugs (e.g., quinidine, amiodarone): may cause serious cardiac arrhythmias.

Moderate Interactions (Monitor Closely)

• NSAIDs: may enhance central nervous system stimulation.
• Theophylline: increased plasma concentrations leading to toxicity.
• Rifampin: may lower moxifloxacin levels, reducing efficacy.